In a new report on Quebec’s Valeant Pharmaceuticals, short-seller Citron Research says the stock is "toxic" and predicts the drug company will soon have difficulty paying its debt as it undergoes investigation.
Source:CBC | Business News http://ift.tt/1GI208V
0 commentaires:
Enregistrer un commentaire